Rituxan is an FDA-approved monoclonal antibody indicated for treating blood cancers
-
Drug News
Rituxan for the Treatment of Non-Hodgkin’s Lymphoma, US
Drug NameDevelopersTherapy ClassCurrent IndicationsMarket SectorDevelopment StatusRituxanBiogen Idec / Genentech (Roche)Anti-CD20 monoclonal antibodyNHL, CLL, BL, BLL, B-AL, RA, GPA and MPA,…
Read More »